E9-1052. Importer of Controlled Substances; Notice of Application  

  • Start Preamble

    Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

    Therefore, in accordance with Title 21 Code of Federal Regulations § 1301.34(a), this is notice that on October 23, 2008, Noramco Inc., 1440 Olympic Drive, Athens, Georgia 30601, has made letter to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic class Thebaine (9333), a controlled substance listed in schedule II.

    The company plans to import analytical reference standards for distribution to its customers for research purposes.

    Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic class of controlled substance may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 1316.47.

    Any such comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than February 20, 2009.

    This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR § 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745-46), all applicants for registration to import the basic class of any controlled substances in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

    Start Signature

    Dated: January 9, 2009.

    Joseph T. Rannazzisi,

    Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

    End Signature End Preamble

    [FR Doc. E9-1052 Filed 1-16-09; 8:45 am]

    BILLING CODE 4410-09-P

Document Information

Published:
01/21/2009
Department:
Drug Enforcement Administration
Entry Type:
Notice
Document Number:
E9-1052
Pages:
3642-3642 (1 pages)
PDF File:
e9-1052.pdf